Last reviewed · How we verify
sofosbuvir and daclatasvir
sofosbuvir and daclatasvir is a Small molecule drug developed by Tehran University of Medical Sciences. It is currently FDA-approved. Also known as: Sovodak, Sovaldi, Sovaldi®, GS-7977, Daklinza®,BMS-790052.
Sofosbuvir is a medication used to treat Hepatitis C Virus Infection, Chronic Hepatitis C, Liver Cirrhosis, and Chronic Hepatitis C. It is often used in combination with other medications, such as Ribavirin, and has been studied in combination with LDV/SOF for these conditions.
At a glance
| Generic name | sofosbuvir and daclatasvir |
|---|---|
| Also known as | Sovodak, Sovaldi, Sovaldi®, GS-7977, Daklinza®,BMS-790052, Sovaldi® |
| Sponsor | Tehran University of Medical Sciences |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of DAA Treatment for Children and Adolescents With Active HCV Infection in Cambodia (NA)
- Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19 (PHASE2)
- Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs
- Impact of Direct-acting Antiviral Drugs on The Patterns of Gut Microbiota in Patients With HCV Related Chronic Liver Diseases
- An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease (PHASE2)
- Antiviral Agents Against COVID-19 Infection (PHASE2, PHASE3)
- DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C) (PHASE4)
- A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- sofosbuvir and daclatasvir CI brief — competitive landscape report
- sofosbuvir and daclatasvir updates RSS · CI watch RSS
- Tehran University of Medical Sciences portfolio CI
Frequently asked questions about sofosbuvir and daclatasvir
What is sofosbuvir and daclatasvir?
Who makes sofosbuvir and daclatasvir?
Is sofosbuvir and daclatasvir also known as anything else?
What development phase is sofosbuvir and daclatasvir in?
Related
- Manufacturer: Tehran University of Medical Sciences — full pipeline
- Also known as: Sovodak, Sovaldi, Sovaldi®, GS-7977, Daklinza®,BMS-790052, Sovaldi®
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing